10 Best Performing Growth Stocks in 2025

3. Verona Pharma plc (NASDAQ:VRNA)

YTD-Performance: 27.28%

Number of Hedge Fund Holders: 42

Verona Pharma plc (NASDAQ:VRNA) is a biopharmaceutical company based in the United Kingdom that focuses on creating and commercializing treatments for respiratory diseases. It is working to develop inhaled Ensifentrine for chronic obstructive pulmonary disease. Ensifentrine is a molecule that inhibits phosphodiesterase 3 and 4 and combines bronchodilator and non-steroidal anti-inflammatory activities.

On February 28, Analyst Edward Nash from Canaccord Genuity maintained a Buy rating on the stock with a price target of $72. Nash likes the company’s market position and potential for growth. Ohtuvayre, which is one of the leading drugs of the company, had impressive sales in its first full quarter, which exceeded expectations. Moreover, the sales projections for 2025 are expected to increase as a result of this strong performance. The analyst further noted that the drug’s unique mechanism and the large COPD patient population contribute to its success. Verona Pharma plc (NASDAQ:VRNA) plans to introduce Ohtuvayre to the EU and UK markets and continue developments in Greater China, which supports the positive outlook. It is one of the best-performing growth stocks in 2025.